ClinicalTrials.gg
CompletedNCT02336360Updated Aug 11, 2020Results posted

Augmenting Flortaucipir Dosimetry Estimates

A Phase 1 interventional study of Flortaucipir F18 in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
20th of 22
6 · median 70
Started
2015
with 3 others
Phase 1
10 of 22
2 open now
Registered
7th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 20th largest by enrollment, is one of 4 that started in 2015, is one of 10 in phase 1, and was the 7th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who passed screening in an Avid-sponsored study in which flortaucipir will be administered

Exclusion criteria

Exclusion Criteria:

  • Subjects who have withdrawn
  • Investigator or sponsor believes it is in the best interest of the subject to be removed from the trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Urine Analysis

    Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.

    Drug: Flortaucipir F18

Interventions

  • No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid

06

What researchers measure

Primary outcomes

  1. Urine Analysis - Total Integrated Radioactivity Excreted in Urine

    Total integrated radioactivity excreted in urine over time will be determined to augment previous radiation dosimetry calculations.

    Time frame: 0-360 minutes post injection

07

Results

Posted Aug 11, 2020

Participant flow

Enrollment occurred from Jan-Jun 2015 from Avid sponsored study 18F-AV-1451-A05 (NCT02016560)

Participant flow — Overall Study
MilestoneUrine Analysis
Started6
Completed6
Not completed0

Outcome measures

PrimaryUrine Analysis - Total Integrated Radioactivity Excreted in Urine

Total integrated radioactivity excreted in urine over time will be determined to augment previous radiation dosimetry calculations.

Time frame:
0-360 minutes post injection
Reported as:
Mean · megabecquerel-hours per megabecquerel
Urine Analysis - Total Integrated Radioactivity Excreted in Urine
megabecquerel-hours per megabecquerelUrine Analysis
Urine Analysis - Total Integrated Radioactivity Excreted in Urine0.1413 ± 0.07216

Adverse events

Collected over AEs were not collected in this study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Urine Analysis———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Urine Analysis
Mean68.2 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Urine Analysis
Female2
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Urine Analysis
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Urine Analysis
United States6
08

Study locations

1 site
  • Molecular NeuroImaging
    New Haven, Connecticut 06510, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2015
First posted
Jan 13, 2015
Start
Jan 2015
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Aug 11, 2020
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02336360
Responsible party
Sponsor
First posted
Jan 13, 2015
Start date
Jan 2015
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Aug 11, 2020
Last update
Aug 11, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion